Schedule 13D/A: Accelmed Reports 1.44M Shares (27.4%) in SSKN

Rhea-AI Filing Summary

Accelmed Partners and affiliated reporting persons disclose beneficial ownership of 1,441,835 shares of Strata Skin Sciences common stock, representing 27.4% of the outstanding shares. This Amendment No. 2 to Schedule 13D reports that the percentage calculation is based on 5,268,708 shares outstanding following a September 4, 2025 registered direct offering by the issuer that issued 1,097,547 new shares. The filing amends prior Schedule 13D information solely to reflect the change in percent of class; no transactions in the issuer's shares by the reporting persons occurred in the past 60 days. The reporting persons and signatory for this filing is Uri Geiger in his capacity as Managing Partner.

Positive

• Material disclosure of ownership: Reporting persons clearly disclose beneficial ownership of 1,441,835 shares representing 27.4% of outstanding common stock.
• Amendment transparency: Filing explicitly explains that the change in percent of class is due to the issuer's registered direct offering that issued 1,097,547 new shares.
• No recent transactions: Reporting persons state they have not engaged in any transactions in the issuer's shares during the past 60 days.

Negative

• None.

Insights

Financial Analyst

TL;DR: Accelmed and affiliates hold a material 27.4% stake after a dilution event; this is a significant ownership disclosure for SSKN shareholders.

The filing shows 1,441,835 shares beneficially owned by Accelmed-related reporting persons, representing 27.4% of Strata Skin Sciences' 5,268,708 shares outstanding after the issuer's September 4, 2025 registered direct offering that issued 1,097,547 shares. The amendment is limited to recalculating percent ownership and does not report any purchases or sales by the reporting persons in the last 60 days. For investors, a single disclosed holder at this ownership level can influence shareholder votes and strategic decisions, though the filing does not state any control actions or transactions.

Corporate Governance Expert

TL;DR: The amendment corrects ownership percentages after issuance; it discloses significant stake but reports no change in holdings or governance actions.

The document amends prior Schedule 13D to reflect the issuer's new share count following a registered direct offering. Reporting persons continue to report shared voting and dispositive power over 1,441,835 shares. The filing contains no statements about plans, proposals or transactions and confirms no shares were transacted in the past 60 days. From a governance perspective, the filing provides necessary transparency but does not itself indicate any imminent board or strategic moves.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 2)

STRATA Skin Sciences

(Name of Issuer)

Common stock, $0.001 par value per share

(Title of Class of Securities)

86272A305

(CUSIP Number)

Accelmed Partners, L.P.
1670 Daytonia Road, Attn: Uri Geiger
Miami Beach, FL, 33141
(786) 826-9118

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

09/04/2025

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No. 86272A305

1

Name of reporting person

Accelmed Partners, L.P.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 1,441,835.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 1,441,835.00

11

Aggregate amount beneficially owned by each reporting person

1,441,835.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

27.4 %

14

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person:

The percentages used herein are calculated based upon 5,268,708 shares of Common Stock outstanding immediately following the September 4, 2025 closing of the issuer's registered direct offering as described in "Item 1 - Explanatory Note" below.

SCHEDULE 13D

CUSIP No. 86272A305

1

Name of reporting person

Accelmed Partners (GP), L.P.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 1,441,835.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 1,441,835.00

11

Aggregate amount beneficially owned by each reporting person

1,441,835.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

27.4 %

14

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person:

The percentages used herein are calculated based upon 5,268,708 shares of Common Stock outstanding immediately following the September 4, 2025 closing of the issuer's registered direct offering as described in "Item 1 - Explanatory Note" below.

SCHEDULE 13D

CUSIP No. 86272A305

1

Name of reporting person

Accelmed Growth Partners (AGP) Ltd.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 1,441,835.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 1,441,835.00

11

Aggregate amount beneficially owned by each reporting person

1,441,835.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

27.4 %

14

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person:

The percentages used herein are calculated based upon 5,268,708 shares of Common Stock outstanding immediately following the September 4, 2025 closing of the issuer's registered direct offering as described in "Item 1 - Explanatory Note" below.

SCHEDULE 13D

CUSIP No. 86272A305

1

Name of reporting person

Accelmed Growth Partners Management Ltd.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 1,441,835.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 1,441,835.00

11

Aggregate amount beneficially owned by each reporting person

1,441,835.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

27.4 %

14

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person:

The percentages used herein are calculated based upon 5,268,708 shares of Common Stock outstanding immediately following the September 4, 2025 closing of the issuer's registered direct offering as described in "Item 1 - Explanatory Note" below.

SCHEDULE 13D

CUSIP No. 86272A305

1

Name of reporting person

Uri Geiger

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

ISRAEL

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 1,441,835.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 1,441,835.00

11

Aggregate amount beneficially owned by each reporting person

1,441,835.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

27.4 %

14

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person:

The percentages used herein are calculated based upon 5,268,708 shares of Common Stock outstanding immediately following the September 4, 2025 closing of the issuer's registered direct offering as described in "Item 1 - Explanatory Note" below.

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Common stock, $0.001 par value per share
(b)	Name of Issuer: STRATA Skin Sciences
(c)	Address of Issuer's Principal Executive Offices: 5 WALNUT GROVE DRIVE, SUITE 140, HORSHAM, PENNSYLVANIA , 19044.
Item 1 Comment: Explanatory Note This Amendment No. 2 to Schedule 13D (this "Schedule 13D/A") is being filed to amend the Schedule 13D filed with the U.S. Securities and Exchange Commission ("SEC") on April 3, 2018, as amended on July 18, 2024 (together, the "Initial 13D"). The Reporting Persons are filing this 13D/A solely to report a change in percent of class due to the September 4, 2025 issuance by Strata Skin Sciences, Inc. of 1,097,547 shares of Common Stock in a registered direct offering to third party investors (the "Offering"). Upon closing of the Offering, there are a total of 5,268,708 shares of Common Stock outstanding. All capitalized terms contained herein but not otherwise defined shall have the meanings ascribed to such terms in the Initial 13D.
Item 5.	Interest in Securities of the Issuer
(a)	See rows (11) and (13) of the cover pages to this Schedule 13D/A for the aggregate number of shares of Common Stock and percentages beneficially owned by each of the Reporting Persons. The percentages used herein are calculated based upon 5,268,708 shares of Common Stock outstanding immediately following the September 4, 2025 closing of the issuer's registered direct offering as described in "Item 1 - Explanatory Note" above.
(b)	See rows (7) through (10) of the cover pages to this Schedule 13D/A for the number of Common Shares as to which each Reporting Person has the sole or shared power to vote or direct the vote and sole or shared power to dispose or to direct the disposition.
(c)	The Reporting Persons have not engaged in any transactions with respect to shares of the Common Stock during the past sixty (60) days.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Accelmed Partners, L.P.

Signature:	/s/ Uri Geiger
Name/Title:	Uri Geiger/Managing Partner
Date:	09/05/2025

Accelmed Partners (GP), L.P.

Signature:	/s/ Uri Geiger
Name/Title:	Uri Geiger/Managing Partner
Date:	09/05/2025

Accelmed Growth Partners (AGP) Ltd.

Signature:	/s/ Uri Geiger
Name/Title:	Uri Geiger/Managing Partner
Date:	09/05/2025

Accelmed Growth Partners Management Ltd.

Signature:	/s/ Uri Geiger
Name/Title:	Uri Geiger/Managing Partner
Date:	09/05/2025

Uri Geiger

Signature:	/s/ Uri Geiger
Name/Title:	Uri Geiger, an individual
Date:	09/05/2025

FAQ

What stake does Accelmed Partners report in Strata Skin Sciences (SSKN)?

Accelmed Partners and affiliated reporting persons report beneficial ownership of 1,441,835 shares, representing 27.4% of SSKN common stock based on 5,268,708 shares outstanding.

Why was this Schedule 13D/A filed for SSKN?

The amendment was filed to update the reported percent of class following Strata Skin Sciences' September 4, 2025 registered direct offering that issued 1,097,547 new shares.

Did the reporting persons buy or sell SSKN shares recently?

No. The filing states the reporting persons have not engaged in any transactions with respect to SSKN common stock during the past 60 days.

Who signed the Schedule 13D/A for Accelmed?

The Schedule 13D/A was signed by Uri Geiger in his capacity as Managing Partner on behalf of the reporting persons and individually, dated 09/05/2025.

How many shares did Strata Skin Sciences issue in the registered direct offering?

The issuer issued 1,097,547 shares in the registered direct offering that closed on September 4, 2025.